Prevnar 13™

BIOLOGICAL18 trials

Sponsors

GlaxoSmithKline, Merck Sharp & Dohme LLC

Conditions

Bacterial InfectionsHaemophilus Influenzae Type bInfections, StreptococcalPneumococcal InfectionsPneumococcal VaccinesPneumonia, PneumococcalVirus Diseases

Phase 1

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

CompletedNCT02531373

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2015-09-15End: 2017-04-14Updated: 2019-04-02

Phase 2

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

CompletedNCT01616459

GlaxoSmithKlineInfections, Streptococcal

Start: 2012-07-11End: 2014-01-22Updated: 2019-07-16

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

CompletedNCT02573181

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2015-10-30End: 2016-01-28Updated: 2019-08-14

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

CompletedNCT02987972

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2017-03-21End: 2018-10-04Updated: 2019-10-23

Phase 3

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

CompletedNCT01000974

GlaxoSmithKlineHaemophilus Influenzae Type b

Start: 2010-06-18End: 2013-07-17Updated: 2018-07-12

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

CompletedNCT01337167

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-04-19End: 2013-05-09Updated: 2018-11-15

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

CompletedNCT01340937

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-05-10End: 2013-07-26Updated: 2018-11-15

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

CompletedNCT02225587

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2014-08-28End: 2015-07-06Updated: 2021-11-02

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

CompletedNCT03480763

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-06-22End: 2019-12-23Updated: 2021-11-02

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

CompletedNCT03480802

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-07-06End: 2020-01-17Updated: 2022-05-05

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

CompletedNCT03547167

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-07-16End: 2020-01-20Updated: 2021-01-15

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

CompletedNCT03565900

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-09-12End: 2021-11-04Updated: 2023-07-28

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

CompletedNCT03620162

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-10-18End: 2020-12-14Updated: 2023-01-17

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

CompletedNCT03692871

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-12-14End: 2021-03-26Updated: 2023-07-28

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

CompletedNCT03731182

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-01-23End: 2020-06-08Updated: 2021-06-16

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

CompletedNCT03893448

Merck Sharp & Dohme LLCPneumococcal Infections, Pneumococcal Vaccines

Start: 2019-06-19End: 2021-05-24Updated: 2023-07-28

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

CompletedNCT03921424

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-11-05End: 2021-05-03Updated: 2023-06-07

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

CompletedNCT03950856

Merck Sharp & Dohme LLCPneumococcal Infections, Pneumonia, Pneumococcal

Start: 2019-06-12End: 2020-04-03Updated: 2021-04-12

Related Papers

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.

2025-12-19

The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay

Vaccine2025-08-011 citations

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up

Human Vaccines & Immunotherapeutics2025-06-192 citations

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

Expert Review of Vaccines2023-10-176 citations

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)

Clinical Infectious Diseases2023-06-2013 citations

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV

AIDS2023-03-173 citations

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Vaccine2023-01-0141 citations

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

2022-12-1312 citations

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study

Blood Advances2022-11-168 citations

Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).

2022-01-149 citations

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)

Open Forum Infectious Diseases2021-12-1816 citations

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV

AIDS2021-11-0925 citations

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).

2021-09-0431 citations

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Human Vaccines & Immunotherapeutics2021-05-2115 citations

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

The Pediatric Infectious Disease Journal2020-05-2663 citations

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

2019-02-1545 citations

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

2018-11-1434 citations

Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.

2017-05-20

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants.

2017-02-0116 citations

1112A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants

Open Forum Infectious Diseases2014-01-01